{"key":"op_284_TR","page":{"url":"https://jp.bookimed.com/clinics/country=turkey/procedure=targeted-therapy/","procedure":{"id":284,"slug":"targeted-therapy","name":"分子標的治療","name_forms":{"plural":{"status":"missing","reason":"not_collected"},"genitive":{"status":"missing","reason":"not_collected"}},"type":"therapy","grammar_number":{"status":"missing","reason":"not_collected"},"parent_id":"oncology","family_attribute":{"status":"missing","reason":"not_collected"}},"country":{"id":46,"iso":"TR","name":"トルコ"},"currency":"USD","data_date":"2026-10-06"},"pages":{"clinics_url":"https://jp.bookimed.com/clinics/country=turkey/procedure=targeted-therapy/","cost_url":"https://jp.bookimed.com/clinics/country=turkey/procedure=targeted-therapy/cost/","best_url":{"status":"missing","reason":"template not live"}},"price":{"from":3000,"to":6000,"avg":{"value":3000,"method":"median","source":"clinics"},"us":{"from":9000,"to":20000},"uk":{"from":3800,"to":9500},"by_technique":{"status":"missing","reason":"not_collected"},"by_city":[{"city":"イスタンブール","from":3000},{"city":"ブルサ","from":2200},{"city":"イズミル","from":3500},{"city":"アンタルヤ","from":3500}],"per_unit":{"status":"missing","reason":"not_collected"},"factors":{"status":"missing","reason":"not_collected"},"tiers":{"status":"missing","reason":"no_offers"},"comparison":[{"country_iso":"UA","from":1800,"to":4800},{"country_iso":"FR","from":6500,"to":13000},{"country_iso":"GB","from":3800,"to":9500},{"country_iso":"US","from":9000,"to":20000},{"country_iso":"IL","from":6500,"to":12500},{"country_iso":"MX","from":3500,"to":8000},{"country_iso":"DE","from":3000,"to":50000},{"country_iso":"CA","from":9000,"to":24000},{"country_iso":"AE","from":6500,"to":14000},{"country_iso":"TH","from":1000,"to":9000},{"country_iso":"PL","from":2500,"to":6000},{"country_iso":"KR","from":6500,"to":12500},{"country_iso":"CZ","from":3500,"to":8000},{"country_iso":"AT","from":9000,"to":21000},{"country_iso":"ES","from":13700,"to":{"status":"missing","reason":"not_collected"}},{"country_iso":"IT","from":4500,"to":9000},{"country_iso":"CN","from":3500,"to":11000},{"country_iso":"AU","from":9000,"to":21000},{"country_iso":"IN","from":1000,"to":8500},{"country_iso":"MY","from":6500,"to":13500},{"country_iso":"VN","from":4500,"to":9500},{"country_iso":"BR","from":4500,"to":7000},{"country_iso":"EG","from":1000,"to":4800}],"base_country":"US","base_is_fallback":false},"savings":{"pct":67,"variant":">=15%"},"package":{"included":{"status":"missing","reason":"no_offers"},"excluded":{"status":"missing","reason":"no_offers"},"extra_charges":{"status":"missing","reason":"not_collected"}},"clinics":{"count":28,"items":[{"id":96,"name":"Memorial Şişli Hospital","city":"Istanbul","rating":4.6,"reviews_count":436,"accreditations":["International Organization for Standardization","Joint Commission International"],"rank":1,"has_procedure":true,"why_ranked":"JCI-accredited oncology department with access to advanced targeted drugs and personalized therapy plans. Follows NCCN and ESMO protocols for precise treatment.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":87,"name":"Anadolu Medical Center","city":"Istanbul","rating":4.6,"reviews_count":544,"accreditations":["Planetree's Gold Certificate","International Accreditation System for Interventional Oncology Services (IASIOS)","Patient choice in Oncology & Hematology Oncology","Patient Choice for Basic Check-up","Johns Hopkins Medicine","Organisation of European Cancer Institutes Certificate","European Society for Medical Oncology","Joint Commission International","International Organization for Standardization","World's Best Hospitals 2026 by Newsweek"],"rank":2,"has_procedure":true,"why_ranked":"Offers specialized PSMA-targeted therapies with JCI accreditation and collaboration with Johns Hopkins Medicine. Doctors have 40+ publications in tumor biology and targeted therapy.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":410,"name":"Memorial Bahçelievler Hospital","city":"Istanbul","rating":4.6,"reviews_count":165,"accreditations":["International Organization for Standardization","Joint Commission International"],"rank":3,"has_procedure":true,"why_ranked":"Specializes in Lutetium-177 therapy with a dedicated targeted therapy team led by an experienced oncologist. Offers precise diagnostics with 3T MRI and innovative Elekta Versa HD radiotherapy system.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":426,"name":"Hisar Hospital Intercontinental","city":"Istanbul","rating":4.5,"reviews_count":266,"accreditations":["Joint Commission International","Turkish Medical Association (Türk Tabıplerı Bırliği)","Turkish Medical Association","Patient choice in Oncology & Hematology Oncology","Best patient assistance","Best clinic for radiotherapy"],"rank":4,"has_procedure":true,"why_ranked":"JCI-accredited hospital with specialized oncology team. Offers Lutetium-177 therapy for targeted cancer treatment. Doctors recommend personalized treatment plans based on molecular test results.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":7176,"name":"Memorial Göztepe Hospital","city":"Istanbul","rating":4.8,"reviews_count":9,"accreditations":{"status":"missing","reason":"not_collected"},"rank":5,"has_procedure":true,"why_ranked":"Multidisciplinary tumor board designs targeted therapy plans based on genetic profiling. Real-time AI-supported MRI and PET/CT track progress. Turkey's first JCI-accredited hospital.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":417,"name":"Memorial Antalya Hospital","city":"Antalya","rating":4.6,"reviews_count":152,"accreditations":["Joint Commission International"],"rank":6,"has_procedure":true,"why_ranked":"Follows NCCN and ESMO protocols with a multidisciplinary team approach. Offers personalized treatment plans based on genetic testing. JCI-accredited hospital with 94% patient recommendation rate.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":432,"name":"Memorial Ataşehir Hospital","city":"Istanbul","rating":4.5,"reviews_count":55,"accreditations":["Joint Commission International"],"rank":7,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":94,"name":"Medical Park Göztepe Hospital Complex","city":"Istanbul","rating":4.4,"reviews_count":35,"accreditations":["International Organization for Standardization","Joint Commission International","Robotic Surgery Center of Exellence","Colorectal Surgery Center for Excellence","Bariatric Surgery Center of Excellence"],"rank":8,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":3418,"name":"Valued Med Hub Hospitals","city":"Istanbul","rating":4.9,"reviews_count":59,"accreditations":["Turkish Medical Association","International Health Tourism Authorization Certificate"],"rank":9,"has_procedure":true,"why_ranked":"Offers specialized Lutetium-177 therapy and personalized treatment plans based on genetic testing. Doctors have performed 1,100+ procedures with a focus on gastrointestinal cancers.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":85,"name":"Medipol Mega University Hospital","city":"Istanbul","rating":4.5,"reviews_count":495,"accreditations":["Joint Commission International","Patient choice in Pediatric Oncology & Hematology Oncology"],"rank":10,"has_procedure":true,"why_ranked":"Offers specialized Lutetium-177 therapy for targeted cancer treatment. JCI-accredited oncology hospital with PET-CT and advanced radiotherapy equipment including Trilogy and TrueBeam LINACs.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":5613,"name":"VM Medical Park Florya Hospital","city":"Istanbul","rating":5,"reviews_count":1,"accreditations":["International Organization for Standardization","Joint Commission International","Robotic Surgery Center of Exellence","Colorectal Surgery Center for Excellence","Bariatric Surgery Center of Excellence"],"rank":11,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":5615,"name":"Medical Park Antalya Hospital Complex","city":"Antalya","rating":4.4,"reviews_count":8,"accreditations":["International Health Tourism Authorization Certificate"],"rank":12,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":276,"name":"Neolife Medical Center","city":"Istanbul","rating":4.7,"reviews_count":19,"accreditations":["International Organization for Standardization","Joint Commission International"],"rank":13,"has_procedure":true,"why_ranked":"Molecular diagnostics and mutation analysis guide which targeted therapy is chosen, with complex cases reviewed by a Multidisciplinary Tumor Board. JCI-accredited, with on-site PET/CT and MRI.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":765,"name":"Istinye University Liv Hospital Bahcesehir","city":"Istanbul","rating":4.2,"reviews_count":19,"accreditations":["Best clinic for radiotherapy","Best price for PET/CT","Turkish Medical Association"],"rank":14,"has_procedure":true,"why_ranked":"Offers specialized Lutetium-177 therapy for targeted cancer treatment. Combines university research with clinical expertise for complex cases.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":1686,"name":"Quartz Hospital","city":"Istanbul","rating":4.7,"reviews_count":165,"accreditations":["Given to the doctor International Society of Aesthetic Plastic Surgery (ISAPS) Сertificate"],"rank":15,"has_procedure":true,"why_ranked":"Offers targeted therapy with mandatory dermatologist consultation for personalized treatment plans. Clinics performs 6,500+ procedures annually with a 91% recommendation rate.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":5442,"name":"Medipol Acibadem District Hospital","city":"Istanbul","rating":5,"reviews_count":3,"accreditations":["Joint Commission International"],"rank":16,"has_procedure":true,"why_ranked":"Offers comprehensive genetic testing to guide targeted therapy decisions. Includes detailed follow-up and pathology revisions to personalize treatment.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":1173,"name":"Emsey Hospital","city":"Istanbul","rating":4.1,"reviews_count":42,"accreditations":["The Baby-friendly Hospital Initiative (BFHI) by WHO and UNICEF","Turkish Medical Association","TEMOS International Healthcare Accreditation","Certification according to DIN EN ISO 9001 by TÜV NORD CERT","International Health Tourism Authorization Certificate","International Organization for Standardization"],"rank":17,"has_procedure":true,"why_ranked":"Offers specialized nuclear medicine therapies including Lutetium-177, with JCI accreditation for international quality standards. 33,500+ patients treated annually with comprehensive diagnostic package including genetic testing.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":1547,"name":"Estophia Hospital","city":"Istanbul","rating":4.4,"reviews_count":49,"accreditations":{"status":"missing","reason":"not_collected"},"rank":18,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":1169,"name":"Hermes Clinics (Hermes Clinics A.Ş.)","city":"Ankara","rating":4.5,"reviews_count":20,"accreditations":["Joint Commission International"],"rank":19,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":4904,"name":"Medipol Bahçelievler Univesity Hospital","city":"Istanbul","rating":4.5,"reviews_count":2,"accreditations":["Joint Commission International"],"rank":20,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":1317,"name":"Medicana Sivas Hospital","city":"Sivas","rating":5,"reviews_count":1,"accreditations":{"status":"missing","reason":"not_collected"},"rank":21,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":3887,"name":"Private Koru Ankara Hospital","city":"Ankara","rating":2,"reviews_count":1,"accreditations":["Turkish Medical Association","Joint Commission International"],"rank":22,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":1602,"name":"Acibadem Altunizade Clinic","city":"Istanbul","rating":4.4,"reviews_count":7,"accreditations":["International Organization for Standardization","Joint Commission International","LEED Platinum Sertificate for ECO Buildings"],"rank":23,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":1780,"name":"Medistanbul Hospital","city":"Istanbul","rating":{"status":"missing","reason":"not_collected"},"reviews_count":{"status":"missing","reason":"not_collected"},"accreditations":{"status":"missing","reason":"not_collected"},"rank":24,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":4078,"name":"Uniqacare Clinic","city":"Istanbul","rating":{"status":"missing","reason":"not_collected"},"reviews_count":{"status":"missing","reason":"not_collected"},"accreditations":["Turkish Medical Association"],"rank":25,"has_procedure":true,"why_ranked":"Offers specialized Lutetium-177 therapy, an advanced form of targeted radiation treatment for cancer.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":4441,"name":"EKOL International HOSPITALS - İzmir","city":"İzmir","rating":{"status":"missing","reason":"not_collected"},"reviews_count":{"status":"missing","reason":"not_collected"},"accreditations":["Turkish Medical Association","International Organization for Standardization","International Health Tourism Authorization Certificate"],"rank":26,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":4464,"name":"Private Medicabil Hospital","city":"Bursa","rating":{"status":"missing","reason":"not_collected"},"reviews_count":{"status":"missing","reason":"not_collected"},"accreditations":["International Organization for Standardization","International Health Tourism Authorization Certificate","Joint Commission International"],"rank":27,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":4960,"name":"BP Klinik","city":"Turkey","rating":{"status":"missing","reason":"not_collected"},"reviews_count":{"status":"missing","reason":"not_collected"},"accreditations":["Turkish Medical Association","International Health Tourism Authorization Certificate","Turkish Medical Association (Türk Tabıplerı Bırliği)"],"rank":28,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}}]},"doctors":{"count":23,"languages":{"status":"missing","reason":"not_collected"}},"cities":[{"id":107,"slug":"istanbul","name":"イスタンブール","clinics_count":3,"price_from":3000,"profile":{"city_type":"Largest city in Turkey, megacity","access":["Sabiha Gökçen Airport (SAW), 32 km southeast of city center"],"sources":["https://en.wikipedia.org/wiki/Istanbul","https://en.wikipedia.org/wiki/Sabiha_G%C3%B6k%C3%A7en_International_Airport"],"checked_at":"2026-11-03","status":"ok"}},{"id":348,"slug":"bursa","name":"ブルサ","clinics_count":{"status":"missing","reason":"not_collected"},"price_from":2200,"profile":{"city_type":"City in northwestern Turkey","access":["Yenişehir Airport (YEI), 49 km from the city center"],"sources":["https://en.wikipedia.org/wiki/Bursa"],"checked_at":"2026-11-03","status":"ok"}},{"id":395,"slug":"izmir","name":"イズミル","clinics_count":{"status":"missing","reason":"not_collected"},"price_from":3500,"profile":{"city_type":"Aegean coastal port city in Turkey","access":["Izmir Airport (ADB), 14 km from the city center"],"sources":["https://en.wikipedia.org/wiki/%C4%B0zmir","https://en.wikipedia.org/wiki/Izmir_Adnan_Menderes_Airport"],"checked_at":"2026-11-03","status":"ok"}},{"id":382,"slug":"antalya","name":"アンタルヤ","clinics_count":{"status":"missing","reason":"not_collected"},"price_from":3500,"profile":{"city_type":"Major Mediterranean coastal city in Turkey","access":["Antalya Airport (AYT), 13 km from the city center"],"sources":["https://en.wikipedia.org/wiki/Antalya","https://en.wikipedia.org/wiki/Antalya_Airport"],"checked_at":"2026-11-03","status":"ok"}}],"offers":{"active":{"status":"missing","reason":"no_offers"},"active_with_related":11,"hospital_nights_median":{"status":"missing","reason":"no_offers"},"days_in_country_median":{"status":"missing","reason":"no_offers"},"top_offers":[{"id":"69cfa6076a5b507d7202aefe","clinic_id":96,"clinic_listed":true,"price":6500,"nights":0,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Consultation with a doctor","VIP transfer (premium vehicle service, all transfers between airport, hotel and clinic)"],"excluded":["Accommodation is not included"],"other_services":"Pre-treatment preparation starts the night before. Our patient is admitted to the hospital in the morning. Blood samples are taken in the patient’s room. Some medications are administered intravenously before the treatment. Around noon, once the preparation (synthesis) of the Lu-177 medication is completed, the Lu-177 therapy is administered intravenously in the patient’s room. The patient stays in the hospital for 1 night for observation. The next morning, a whole-body scintigraphy scan is performed using a gamma camera. Discharge procedures begin around noon. ⸻ Follow-up process: Blood tests are required 2 weeks and 4 weeks after the treatment. If everything is progressing well in the blood tests, the second treatment session is planned approximately 6 weeks later. For patients who successfully complete 4 treatment cycles, a Ga-68 PET/CT scan is performed to evaluate the effectiveness of the treatment.","is_package":true},{"id":"69331d0832bd63eea1ffac9b","clinic_id":87,"clinic_listed":true,"price":10000,"nights":0,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Consultation with a doctor","Blood tests","Follow-up examination","Biochemistry blood test","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"Lutetium-177 DOTA Neuroendocrine Radioligand Therapy Program The Lutetium-177 (Lu-177) DOTA Radioligand Therapy Program is an advanced targeted treatment option for patients with somatostatin receptor–positive neuroendocrine tumors. This program integrates molecular imaging assessment and systemic radioligand therapy within a structured and carefully monitored treatment pathway. Prior to therapy, previously performed DOTA PET/CT imaging is reviewed to confirm somatostatin receptor expression and evaluate disease distribution. Treatment eligibility and the final therapy decision are based on this molecular imaging assessment, ensuring an individualized and precisely targeted treatment approach. The therapy utilizes Lutetium-177, a beta-emitting radioisotope attached to a DOTA-based targeting molecule that selectively binds to somatostatin receptor–expressing tumor cells. Once internalized, Lutetium-177 releases therapeutic radiation that damages tumor cell DNA, leading to controlled tumor cell destruction. Because beta radiation has a moderate tissue penetration range, it allows effective treatment of metastatic lesions while maintaining an established and favorable safety profile. The program is conducted under the medical leadership of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, who brings more than 20 years of experience in nuclear medicine and advanced molecular imaging. All treatments are administered in a specialized nuclear medicine department under strict safety and monitoring protocols. The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in Belgium, Russia, and the United States, ensuring high manufacturing standards, quality control, and traceability. The radiopharmaceutical is produced in Non-Carrier-Added (NCA) quality, providing high specific activity and optimized therapeutic performance. Included Services • Nuclear medicine consultation • Blood tests (kidney, liver, hematologic profile) • MAG-3 renal scintigraphy (first cycle only, if clinically indicated) • Lutetium-177 DOTA treatment administration • Post-treatment scan • Medical follow-up by nuclear medicine specialist • Verification of residual radioactivity for flight compatibility The recommended stay is approximately three days per treatment cycle, including arrival and departure, provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety. For patient convenience, cost-efficient partner hotels are available near the hospital, offering daily shuttle service between the hotel and the medical center to ensure smooth and organized logistics throughout the treatment process.","is_package":true},{"id":"6ac4a779c752e7ea1503ef84","clinic_id":426,"clinic_listed":true,"price":7500,"price_before_discount":8000,"nights":1,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Consultation with a doctor","VIP transfer (premium vehicle service, all transfers between airport, hotel and clinic)"],"excluded":["Accommodation is not included"],"other_services":"Lutetium-177 (Lu-177) Radioligand Therapy Lutetium-177 therapy is a targeted radionuclide treatment in which a radioactive substance linked to a specific molecule binds to cancer cells and delivers radiation directly to them. The treatment is administered intravenously under the supervision of a Nuclear Medicine specialist, with monitoring before and after the procedure to ensure safety and treatment effectiveness. Package Includes: Nuclear Medicine specialist consultation Required laboratory tests and medical evaluation Lutetium-177 treatment administration Radiation safety monitoring Post-treatment medical assessment Follow-up recommendations Treatment Duration: According to the patient's clinical condition and treatment protocol Hospitalization: As required by the nuclear medicine team and radiation safety regulations","is_package":true}],"packages":{"status":"missing","reason":"no_offers"},"related_packages":[{"id":"69cfa6076a5b507d7202aefe","clinic_id":96,"clinic_listed":true,"price":6500,"nights":0,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Consultation with a doctor","VIP transfer (premium vehicle service, all transfers between airport, hotel and clinic)"],"excluded":["Accommodation is not included"],"other_services":"Pre-treatment preparation starts the night before. Our patient is admitted to the hospital in the morning. Blood samples are taken in the patient’s room. Some medications are administered intravenously before the treatment. Around noon, once the preparation (synthesis) of the Lu-177 medication is completed, the Lu-177 therapy is administered intravenously in the patient’s room. The patient stays in the hospital for 1 night for observation. The next morning, a whole-body scintigraphy scan is performed using a gamma camera. Discharge procedures begin around noon. ⸻ Follow-up process: Blood tests are required 2 weeks and 4 weeks after the treatment. If everything is progressing well in the blood tests, the second treatment session is planned approximately 6 weeks later. For patients who successfully complete 4 treatment cycles, a Ga-68 PET/CT scan is performed to evaluate the effectiveness of the treatment.","is_package":true,"operation_id":830,"operation_name":"Lutetium-177 therapy"},{"id":"69331d0832bd63eea1ffac9d","clinic_id":87,"clinic_listed":true,"price":10000,"price_before_discount":13000,"nights":0,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Consultation with a doctor","Blood tests","Follow-up examination","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"Lutetium-177 PSMA Prostate Radioligand Therapy Program The Lutetium-177 (Lu-177) PSMA Prostate Radioligand Therapy Program is an advanced targeted treatment option for patients with metastatic, progressive, or treatment-resistant prostate cancer. This program provides a structured and carefully monitored therapeutic pathway designed for precise tumor targeting and controlled systemic treatment. Prior to therapy, previously performed PSMA PET/CT imaging is reviewed to confirm adequate PSMA receptor expression and to evaluate disease distribution. Based on this molecular imaging assessment, treatment eligibility and final therapy planning are determined individually. The therapy utilizes Lutetium-177, a beta-emitting radioisotope linked to a PSMA-targeting molecule that selectively binds to prostate cancer cells. After binding and internalization, Lutetium-177 delivers targeted radiation to tumor tissue, leading to DNA damage and controlled destruction of cancer cells while minimizing exposure to surrounding healthy tissues. The radiopharmaceutical is produced in Non-Carrier-Added (NCA) quality, providing high specific activity and optimized therapeutic performance. Due to the moderate tissue penetration range of beta radiation, Lu-177 PSMA therapy enables effective treatment of metastatic lesions while maintaining a favorable safety profile. This therapy is widely used for advanced prostate cancer patients requiring systemic targeted treatment. The program is conducted under the medical supervision of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, with more than 20 years of experience in nuclear medicine and advanced molecular imaging. All treatments are administered in a specialized nuclear medicine environment under strict safety and monitoring protocols. The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in the United States, ensuring high manufacturing standards, quality control, and traceability. Nuclear medicine consultation Comprehensive laboratory testing to assess kidney, liver, and hematologic function MAG-3 renal scintigraphy Administration of Lutetium-177 PSMA therapy Post-treatment imaging Coordinated follow-up by a nuclear medicine specialist, including verification of residual radioactivity to ensure flight compatibility The recommended stay is approximately three days per treatment cycle, including arrival and departure, provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety. For patient convenience, cost-efficient partner hotels are available near the hospital, offering daily shuttle service between the hotel and the medical center to ensure smooth and organized logistics throughout the treatment process.","is_package":true,"operation_id":830,"operation_name":"Lutetium-177 therapy"},{"id":"69331d0832bd63eea1ffac9b","clinic_id":87,"clinic_listed":true,"price":10000,"nights":0,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Consultation with a doctor","Blood tests","Follow-up examination","Biochemistry blood test","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"Lutetium-177 DOTA Neuroendocrine Radioligand Therapy Program The Lutetium-177 (Lu-177) DOTA Radioligand Therapy Program is an advanced targeted treatment option for patients with somatostatin receptor–positive neuroendocrine tumors. This program integrates molecular imaging assessment and systemic radioligand therapy within a structured and carefully monitored treatment pathway. Prior to therapy, previously performed DOTA PET/CT imaging is reviewed to confirm somatostatin receptor expression and evaluate disease distribution. Treatment eligibility and the final therapy decision are based on this molecular imaging assessment, ensuring an individualized and precisely targeted treatment approach. The therapy utilizes Lutetium-177, a beta-emitting radioisotope attached to a DOTA-based targeting molecule that selectively binds to somatostatin receptor–expressing tumor cells. Once internalized, Lutetium-177 releases therapeutic radiation that damages tumor cell DNA, leading to controlled tumor cell destruction. Because beta radiation has a moderate tissue penetration range, it allows effective treatment of metastatic lesions while maintaining an established and favorable safety profile. The program is conducted under the medical leadership of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, who brings more than 20 years of experience in nuclear medicine and advanced molecular imaging. All treatments are administered in a specialized nuclear medicine department under strict safety and monitoring protocols. The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in Belgium, Russia, and the United States, ensuring high manufacturing standards, quality control, and traceability. The radiopharmaceutical is produced in Non-Carrier-Added (NCA) quality, providing high specific activity and optimized therapeutic performance. Included Services • Nuclear medicine consultation • Blood tests (kidney, liver, hematologic profile) • MAG-3 renal scintigraphy (first cycle only, if clinically indicated) • Lutetium-177 DOTA treatment administration • Post-treatment scan • Medical follow-up by nuclear medicine specialist • Verification of residual radioactivity for flight compatibility The recommended stay is approximately three days per treatment cycle, including arrival and departure, provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety. For patient convenience, cost-efficient partner hotels are available near the hospital, offering daily shuttle service between the hotel and the medical center to ensure smooth and organized logistics throughout the treatment process.","is_package":true,"operation_id":830,"operation_name":"Lutetium-177 therapy"},{"id":"69331d0832bd63eea1ffac9e","clinic_id":87,"clinic_listed":true,"price":11750,"nights":0,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Consultation with a doctor","Blood tests","Follow-up examination","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"Lutetium-177 PSMA Prostate Radioligand Therapy Program with PSMA PET The Lutetium-177 (Lu-177) PSMA Radioligand Therapy Program with PSMA PET is an advanced targeted treatment option for patients with metastatic, progressive, or treatment-resistant prostate cancer. This program integrates molecular imaging and radioligand therapy within a structured and carefully monitored treatment pathway. This treatment utilizes Lutetium-177, a beta-emitting radioisotope attached to a PSMA-targeting molecule that binds specifically to prostate cancer cells. Once internalized, Lutetium-177 releases therapeutic radiation that damages tumor cell DNA, resulting in controlled tumor cell destruction. Because beta radiation has a moderate tissue penetration range, it enables effective treatment of tumor lesions while maintaining an established and favorable safety profile. Before treatment, a specialized PSMA PET/CT scan is performed at our hospital to confirm adequate PSMA receptor expression and evaluate disease distribution. Only patients who meet these molecular criteria are selected for Lutetium-177 PSMA therapy, ensuring an individualized and precisely targeted treatment approach. The program is conducted under the medical leadership of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, who brings more than 20 years of experience in nuclear medicine and advanced molecular imaging. All treatments are administered in a specialized nuclear medicine environment under strict safety and monitoring protocols. The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in Belgium, Russia, and the United States, ensuring high manufacturing standards, quality control, and traceability. The radiopharmaceutical is produced in Non-Carrier-Added (NCA) quality, providing high specific activity and optimized therapeutic performance. Included Services • Nuclear medicine consultation • Blood tests (kidney, liver, hematologic profile) • PSMA PET/CT scan for therapy eligibility assessment • MAG-3 renal scintigraphy (first cycle only, if clinically indicated) • Lutetium-177 PSMA treatment administration • Post-treatment scan • Medical follow-up by nuclear medicine specialist • Verification of residual radioactivity for flight compatibility The recommended stay is approximately four days per treatment cycle, including arrival and departure, provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety. For patient comfort and convenience, cost-efficient partner hotels are available near the hospital, offering daily shuttle service between the hotel and the medical center to ensure a smooth and well-organized treatment experience.","is_package":true,"operation_id":830,"operation_name":"Lutetium-177 therapy"},{"id":"69331d0832bd63eea1ffac9c","clinic_id":87,"clinic_listed":true,"price":11750,"nights":0,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Complete blood count (CBC)","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"Lutetium-177 DOTA Neuroendocrine Radioligand Therapy Program with DOTA PET The Lutetium-177 (Lu-177) DOTA Radioligand Therapy Program is an advanced targeted treatment option for patients with somatostatin receptor–positive neuroendocrine tumors. This program integrates molecular imaging assessment and systemic radioligand therapy within a structured and carefully monitored treatment pathway. Before therapy, a specialized DOTA PET/CT scan is performed and evaluated at our hospital to assess somatostatin receptor expression and determine the extent of disease. Treatment eligibility and the final therapy decision are based on this comprehensive molecular imaging assessment, ensuring that only suitable patients proceed to Lutetium-177 DOTA therapy. The therapy utilizes Lutetium-177, a beta-emitting radioisotope attached to a DOTA-based targeting molecule that selectively binds to somatostatin receptor–expressing tumor cells. Once internalized, Lutetium-177 releases therapeutic radiation that damages tumor cell DNA, leading to controlled tumor cell destruction. Because beta radiation has a moderate tissue penetration range, it allows effective treatment of metastatic lesions while maintaining an established and favorable safety profile. The program is conducted under the medical leadership of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, who brings more than 20 years of experience in nuclear medicine and advanced molecular imaging. All treatments are administered in a specialized nuclear medicine department under strict safety and monitoring protocols. The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in Belgium, Russia, and the United States, ensuring high manufacturing standards, quality control, and traceability. The radiopharmaceutical is produced in Non-Carrier-Added (NCA) quality, providing high specific activity and optimized therapeutic performance. Included Services • Nuclear medicine consultation • Blood tests (kidney, liver, hematologic profile) • DOTA PET/CT scan for therapy eligibility assessment • MAG-3 renal scintigraphy (first cycle only, if clinically indicated) • Lutetium-177 DOTA treatment administration • Post-treatment scan • Medical follow-up by nuclear medicine specialist • Verification of residual radioactivity for flight compatibility The recommended stay is approximately three days per treatment cycle, including arrival and departure, provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety. For patient convenience, cost-efficient partner hotels are available near the hospital, offering daily shuttle service between the hotel and the medical center to ensure smooth and organized logistics throughout the treatment process.","is_package":true,"operation_id":830,"operation_name":"Lutetium-177 therapy"},{"id":"6ac4a779c752e7ea1503ef84","clinic_id":426,"clinic_listed":true,"price":7500,"price_before_discount":8000,"nights":1,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Consultation with a doctor","VIP transfer (premium vehicle service, all transfers between airport, hotel and clinic)"],"excluded":["Accommodation is not included"],"other_services":"Lutetium-177 (Lu-177) Radioligand Therapy Lutetium-177 therapy is a targeted radionuclide treatment in which a radioactive substance linked to a specific molecule binds to cancer cells and delivers radiation directly to them. The treatment is administered intravenously under the supervision of a Nuclear Medicine specialist, with monitoring before and after the procedure to ensure safety and treatment effectiveness. Package Includes: Nuclear Medicine specialist consultation Required laboratory tests and medical evaluation Lutetium-177 treatment administration Radiation safety monitoring Post-treatment medical assessment Follow-up recommendations Treatment Duration: According to the patient's clinical condition and treatment protocol Hospitalization: As required by the nuclear medicine team and radiation safety regulations","is_package":true,"operation_id":830,"operation_name":"Lutetium-177 therapy"},{"id":"6ac4a9622083af9548063bf2","clinic_id":426,"clinic_listed":true,"price":17800,"price_before_discount":18320,"nights":0,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Consultation with a doctor","VIP transfer (premium vehicle service, all transfers between airport, hotel and clinic)"],"excluded":["Accommodation is not included"],"other_services":"Actinium-225 (Ac-225) Targeted Radionuclide Therapy Treatment Description: Actinium-225 targeted radionuclide therapy is an advanced form of nuclear medicine treatment that uses the radioactive isotope Actinium-225 to selectively target and destroy cancer cells. The treatment is generally administered through an intravenous injection and is designed to deliver highly localized radiation to tumor cells while minimizing exposure to surrounding healthy tissues. The treatment is typically considered for selected patients with advanced or metastatic cancers that express specific molecular targets, depending on the patient's diagnosis and eligibility. The Treatment Package Includes: Medical evaluation by a Nuclear Medicine specialist Review of the patient's medical history and previous treatment records Required laboratory and imaging examinations Actinium-225 targeted radionuclide therapy administration Nuclear Medicine specialist consultation and treatment planning Medical monitoring during and after the treatment Post-treatment medical evaluation and follow-up recommendations Important: Patient eligibility and the appropriate Actinium-225 treatment protocol are determined after evaluation of medical records, imaging, laboratory results, and the specific molecular target of the tumor.","is_package":true,"operation_id":1653,"operation_name":"Actinium-225 Therapy"},{"id":"69331d0832bd63eea1ffaca2","clinic_id":87,"clinic_listed":true,"price":24725,"nights":0,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Follow-up examination","Blood tests","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"The Actinium-225 (Ac-225) PSMA Alpha Prostate Premium Program with PSMA PET/CT Scan is an advanced precision therapy developed for patients with metastatic, progressive, or treatment-resistant prostate cancer. This program integrates molecular imaging and targeted alpha therapy within a structured treatment pathway. Before therapy, a specialized PSMA PET/CT scan is performed at our hospital to assess PSMA receptor expression and evaluate the extent of disease. Treatment eligibility is determined based on this molecular imaging assessment, ensuring that only suitable patients proceed to Actinium-225 therapy. The treatment uses Actinium-225, a highly potent alpha-emitting isotope attached to a PSMA-targeting molecule that selectively binds to prostate cancer cells. Once internalized, Actinium-225 releases powerful radiation directly inside the cancer cell, destroying it from within. Because alpha radiation acts over an ultra-short distance, surrounding healthy tissue is largely protected while maintaining strong therapeutic intensity. This makes the therapy particularly valuable for advanced or resistant prostate cancer cases. The program is conducted under the medical leadership of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, who brings more than 20 years of experience in nuclear medicine and advanced molecular imaging, supported by international academic training in the United States. All treatments are administered in a specialized nuclear medicine environment under strict safety and monitoring protocols. The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in the United States, ensuring high manufacturing standards, quality control, and traceability. The treatment package includes nuclear medicine consultation, comprehensive laboratory testing, PSMA PET/CT imaging, renal evaluation when indicated, administration of Actinium-225 PSMA therapy, and structured medical follow-up. The recommended stay is approximately four days per treatment cycle, including arrival and departure, provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety. Cost-efficient partner hotels are available near the hospital, offering daily shuttle service between the hotel and the medical center to ensure convenient and organized logistics throughout the treatment process.","is_package":true,"operation_id":1653,"operation_name":"Actinium-225 Therapy"},{"id":"69331d0832bd63eea1ffaca0","clinic_id":87,"clinic_listed":true,"price":24725,"nights":0,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Consultation with a doctor","Blood tests","Follow-up examination","Biochemistry blood test","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"ACTINIUM-225 DOTA ALPHA NEUROENDOCRINE PREMIUM PROGRAM The Actinium-225 (Ac-225) DOTA Alpha Neuroendocrine Premium Program is an advanced precision therapy developed for patients with progressive, metastatic, or treatment-resistant neuroendocrine tumors. This treatment uses Actinium-225, a highly potent alpha-emitting isotope, attached to a DOTA-based targeting molecule that binds specifically to somatostatin receptor–expressing tumor cells. Once absorbed into the cancer cell, Actinium-225 releases powerful radiation directly inside the tumor, destroying it from within. Because alpha radiation travels only a very short distance, surrounding healthy tissue is largely protected while maintaining strong therapeutic intensity. Before treatment, a specialized DOTA PET/CT scan is performed at our hospital to confirm that the tumor expresses the appropriate receptors and to evaluate disease distribution. Only patients who meet these molecular criteria are selected for Actinium-225 therapy, ensuring a personalized and precisely targeted treatment approach. The program is conducted under the medical leadership of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, who brings more than 20 years of experience in nuclear medicine and advanced molecular imaging, supported by international academic training in the United States. All treatments are administered in a specialized nuclear medicine environment under strict safety and monitoring protocols. The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in the United States, ensuring high manufacturing standards, quality control, and full traceability. The treatment package includes nuclear medicine consultation, comprehensive blood testing to assess kidney, liver, and hematologic function, MAG-3 renal scintigraphy during the first cycle if clinically indicated, administration of Actinium-225 DOTA therapy, and structured medical follow-up by a nuclear medicine specialist. The recommended stay is approximately four days per treatment cycle, including arrival and departure. This duration applies provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety. For patient comfort and convenience, we offer cost-efficient partner hotels located near the hospital, providing daily shuttle service between the hotel and the medical center, allowing for a smooth and organized treatment experience. This program provides a next-generation molecular therapy option for complex neuroendocrine cancer cases within a controlled, internationally coordinated clinical framework.","is_package":true,"operation_id":1653,"operation_name":"Actinium-225 Therapy"},{"id":"69331d0832bd63eea1ffaca1","clinic_id":87,"clinic_listed":true,"price":22955,"nights":0,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Follow-up examination","Blood tests","Consultation with a doctor","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"ACTINIUM-225 PSMA ALPHA PROSTATE PREMIUM PROGRAM The Actinium-225 (Ac-225) PSMA Alpha Prostate Premium Program is an advanced precision therapy developed for patients with metastatic, progressive, or treatment-resistant prostate cancer. This program integrates molecular imaging assessment and targeted alpha therapy within a structured and carefully controlled treatment pathway. Prior to therapy, a previously performed PSMA PET/CT scan is carefully reviewed and evaluated to confirm sufficient PSMA receptor expression and assess disease distribution. Treatment eligibility and the final therapy decision are determined based on this molecular imaging assessment, ensuring an individualized and precisely targeted treatment approach. The therapy utilizes Actinium-225, a highly potent alpha-emitting isotope attached to a PSMA-targeting molecule that selectively binds to prostate cancer cells. Once internalized, Actinium-225 releases powerful radiation directly inside the cancer cell, destroying it from within. Because alpha radiation acts over an ultra-short distance, surrounding healthy tissue is largely protected while maintaining strong therapeutic intensity. This makes the treatment particularly valuable for advanced or resistant prostate cancer cases. The program is conducted under the medical leadership of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, who brings more than 20 years of experience in nuclear medicine and advanced molecular imaging, supported by international academic training in the United States. All treatments are administered in a specialized nuclear medicine environment under strict safety and monitoring protocols. The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in the United States, ensuring high manufacturing standards, quality control, and traceability. The treatment package includes nuclear medicine consultation, comprehensive laboratory testing to assess kidney, liver, and hematologic function, administration of Actinium-225 PSMA therapy, and structured post-treatment follow-up by a nuclear medicine specialist. The recommended stay is approximately four days per treatment cycle, including arrival and departure, provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety. For patient convenience, cost-efficient partner hotels are available near the hospital, offering daily shuttle service between the hotel and the medical center to ensure smooth and organized logistics throughout the treatment process.","is_package":true,"operation_id":1653,"operation_name":"Actinium-225 Therapy"},{"id":"69331d0832bd63eea1ffac9f","clinic_id":87,"clinic_listed":true,"price":22955,"nights":0,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Follow-up examination","Blood tests","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"The Actinium-225 (Ac-225) DOTA Alpha Neuroendocrine Premium Program is an advanced precision therapy developed for patients with progressive, metastatic, or treatment-resistant neuroendocrine tumors. This treatment uses Actinium-225, a highly potent alpha-emitting isotope, attached to a targeting molecule that binds specifically to neuroendocrine tumor cells. Once absorbed into the cancer cell, Actinium-225 releases powerful radiation directly inside the tumor, destroying it from within. Because alpha radiation travels only a very short distance, surrounding healthy tissue is largely protected. Prior to therapy, a previously performed DOTA PET scan is carefully reviewed and consulted in order to confirm sufficient receptor expression and determine whether the patient is suitable for treatment. The therapy decision is based on this molecular imaging evaluation, ensuring an individualized and targeted treatment approach. The program is conducted under the medical leadership of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, who brings over two decades of experience in nuclear medicine and advanced molecular imaging, supported by international academic training in the United States. All treatments are administered in a specialized nuclear medicine environment under strict safety and monitoring protocols. The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in the United States, ensuring high manufacturing standards, quality control, and traceability. The treatment package includes medical consultation, comprehensive blood testing, renal evaluation when indicated, administration of Actinium-225 DOTA therapy, and structured post-treatment follow-up by a nuclear medicine specialist. The recommended stay is approximately four days per treatment cycle, including arrival and departure. This duration applies provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety. For patient comfort, we offer cost-efficient partner hotels located near the hospital, providing daily shuttle service between the hotel and the medical center, ensuring convenient and stress-free logistics during treatment. This program offers a next-generation molecular therapy option for complex neuroendocrine cancer cases within a controlled and internationally coordinated clinical framework.","is_package":true,"operation_id":1653,"operation_name":"Actinium-225 Therapy"}],"other_packages":{"status":"missing","reason":"no_offers"}},"medical":{"indications":["Cancers with molecular targets: HER2, EGFR, ALK, BRAF, BCR-ABL","Hematologic malignancies and solid tumors with a matched targeted agent","Some non-cancer conditions with defined molecular targets"],"contraindications":["Known severe hypersensitivity to the specific agent or its components","Pregnancy and breastfeeding for many agents (agent-specific)","Severe uncontrolled liver, heart or lung dysfunction (relative, agent-dependent)","Clinically significant drug interactions with the specific agent (relative, agent-specific)"],"operation_hours":{"min":0.5,"max":3,"unit":"hours","qualifier":"Per infusion visit; first infusion is longest. Oral agents are taken at home."},"anesthesia":["none"],"sessions_or_stages":{"sessions":{"min":4,"max":13,"unit":"visits","qualifier":"Infusion-based schedule every 1-3 weeks until first imaging; oral agents need no infusion visits."},"stages":[{"code":"biomarker_confirmation","label":"Biomarker confirmation and baseline tests","after":{"min":0,"max":0,"unit":"days","qualifier":"Before first dose."}},{"code":"treatment_start","label":"First dose or infusion","after":{"min":0,"max":7,"unit":"days","qualifier":"Starts once testing is confirmed."}},{"code":"response_assessment","label":"First response imaging","after":{"min":56,"max":90,"unit":"days","qualifier":"After several cycles."}}],"qualifier":"Treatment continues until progression or intolerance; typical first-phase schedule shown."},"hospital_nights":{"value":{"min":0,"max":0,"unit":"nights","qualifier":"Typical oral or infusion-based cycles are given without overnight stay; inpatient stay is not usual for uncomplicated treatment."},"source":"parsed_details"},"treatment_conditions":["outpatient"],"rehabilitation_days":{"min":0,"max":3,"unit":"days","qualifier":"Ordinary activity resumes quickly; longer if infusion reactions or fatigue occur."},"fly_home_after_days":{"min":1,"max":3,"unit":"days","qualifier":"After first dose, oncology team usually wants early tolerance observed; depends on agent and infusion reactions."},"back_to_work_days":{"min":0,"max":3,"unit":"days","qualifier":"Most patients keep working; depends on agent side effects and infusion schedule."},"exercise_resume_weeks":{"min":0,"max":1,"unit":"weeks","qualifier":"Light activity usually continues; intensity limited by fatigue, rash, diarrhea or cardiac precautions."},"final_result_months":{"min":2,"max":6,"unit":"months","qualifier":"Response is judged by imaging after several cycles; depends on tumor type and agent."},"result_longevity":"Response lasts as long as the drug is effective, often months to several years. Acquired resistance eventually develops in many cancers.","main_risks":["Skin reactions such as rash and dryness","Diarrhea, nausea and other gastrointestinal effects","Liver enzyme elevation","Hypertension, cardiac effects or bleeding with certain agents","Infusion reactions with antibody-based agents","Blood count changes"],"complication_rate_pct":{"min":20,"max":50,"unit":"percent","qualifier":"Grade 3-4 adverse events during treatment; any-grade side effects are far more common, varying by agent."},"revision_rate_pct":{"status":"missing","reason":"not_collected"},"success":{"metric":"Objective tumor response rate at first imaging","value":60,"horizon":"2-3 months","source":{"status":"missing","reason":"not_collected"},"evidence_status":"limited"},"scars":"No incisions or scars; only minor puncture marks from IV cannulation.","pain":"Treatment itself is painless apart from IV cannulation. Side effects such as rash, mouth sores or joint aches are usually mild to moderate.","preparation":["Molecular target or biomarker confirmed by tissue or blood testing","Baseline blood tests and organ function assessment","Review of current medications and supplements with the oncology team","Baseline cardiac or other agent-specific assessment where required","Discussion of expected side effects and contraception where relevant"],"recovery_timeline":[{"phase":"Treatment day","description":"Oral dose started or infusion given with observation for reactions.","restrictions":["Report fever or breathing difficulty immediately","Follow agent-specific food and drug rules"]},{"phase":"First 2 weeks","description":"Early side effects such as rash, diarrhea or fatigue may appear and are managed with supportive care.","restrictions":["Avoid sun exposure","Avoid new supplements without approval"]},{"phase":"Ongoing cycles","description":"Treatment continues with periodic blood tests and imaging to assess response.","restrictions":["Contraception where relevant","Avoid grapefruit with some agents"]}],"follow_up_visits":[{"purpose":"assessment","requirement":"routine","after":{"min":7,"max":21,"unit":"days","qualifier":"Early tolerance check with blood tests and side-effect review."}},{"purpose":"result_review","requirement":"routine","after":{"min":56,"max":90,"unit":"days","qualifier":"First response imaging and blood markers; timing depends on agent and cancer type."}}],"sources":{"status":"missing","reason":"not_collected"},"clinic_checks":{"status":"ok","items":[{"id":"C1","text":"Check that your tumor has been tested for the drug's target. Why: the drug is chosen for a specific target found in the tumor","scope":"procedure","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet","host":"cancer.gov","quote":"Most of the time, your tumor will need to be tested to see if it contains targets for which there is a drug.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C2","text":"Check the qualifications of the medical team that will treat you","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Have you checked the qualifications of the medical team treating you?","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C3","text":"Make sure you are clear how your aftercare will be coordinated after treatment abroad","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Ensure you're clear about how your aftercare will be coordinated.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C4","text":"Check that the surgeon who consults with you is the same person who will carry out the procedure","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Check that the surgeon you consult with, will be the same person carrying out the procedure.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C5","text":"Expect two consultations with the treating surgeon before any surgery, which also gives you time to reconsider","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/conditions/cosmetic-procedures/cosmetic-surgery-abroad/","host":"nhs.uk","quote":"You should have 2 consultations with the surgeon treating you before any surgery.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"red_flags":{"status":"ok","items":[{"id":"F1","text":"Pressure to decide quickly, or cheap time-limited offers to book now","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"F2","text":"The doctor you consult may not be the one who actually treats you","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Check that the surgeon you consult with, will be the same person carrying out the procedure.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"F3","text":"Adverts or information promising complete success for the treatment","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Any advert or information that guarantees complete success should raise concerns.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"warning_signs":{"status":"ok","items":[{"id":"W1","text":"Unusual bleeding or bruising during targeted therapy","urgency":"contact_clinic","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/side-effects/bleeding-bruising","host":"cancer.gov","quote":"Some cancer treatments, such as chemotherapy and targeted therapy, can increase your risk of bleeding and bruising.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W2","text":"Diarrhea that lasts or becomes more severe","urgency":"contact_clinic","general":false,"source":{"url":"https://cancer.gov/about-cancer/treatment/side-effects/diarrhea","host":"cancer.gov","quote":"Ask the health care team about when you should call them if the diarrhea lasts or becomes more severe.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W3","text":"Fever higher than your care team expects","urgency":"contact_clinic","general":true,"source":{"url":"https://mdanderson.org/patients-family/diagnosis-treatment/emotional-physical-effects/targeted-therapy-side-effects.html","host":"mdanderson.org","quote":"A fever higher than what your care team told you to expect","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"take_home":{"status":"ok","items":[{"id":"T1","text":"Shows which follow-up tests are due and which doctors are responsible for care","document":"written aftercare plan","source":{"url":"https://www.cdc.gov/cancer/survivors/life-after-cancer/survivorship-care-plans.htm","host":"cdc.gov","quote":"Your plan should say when you need to get follow-up tests, and which doctors are responsible for your care.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":403}},{"id":"T2","text":"Gives the home doctor an up-to-date, clear picture of the treatment received","document":"end of treatment summary","source":{"url":"https://cht.nhs.uk/services/clinical-services/oncology/end-of-treatment-summary","host":"cht.nhs.uk","quote":"It also provides the GP with an up-to-date and clear understanding of the patient's treatment.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"T3","text":"Ask for copies of all prescriptions before you leave","document":"prescription copies","source":{"url":"https://travelhealthpro.org.uk/news/699/travelling-abroad-for-treatment","host":"travelhealthpro.org.uk","quote":"Remember to ask for copies of all your treatment records, including prescriptions, scans and x-rays before you leave.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1}},"parsed_details":{"procedure_type":"therapy","fields":{"anesthesia":["none"],"back_to_work_days":{"min":0,"max":3,"unit":"days","qualifier":"Most patients keep working; depends on agent side effects and infusion schedule."},"complication_rate_pct":{"min":20,"max":50,"unit":"percent","qualifier":"Grade 3-4 adverse events during treatment; any-grade side effects are far more common, varying by agent."},"contraindications":["Known severe hypersensitivity to the specific agent or its components","Pregnancy and breastfeeding for many agents (agent-specific)","Severe uncontrolled liver, heart or lung dysfunction (relative, agent-dependent)","Clinically significant drug interactions with the specific agent (relative, agent-specific)"],"days_in_clinic":{"min":0,"max":0,"unit":"nights","qualifier":"Typical oral or infusion-based cycles are given without overnight stay; inpatient stay is not usual for uncomplicated treatment."},"diagnostic_duration_minutes":null,"diagnostic_preparation":null,"diagnostic_referral_needed":null,"diagnostic_result_time_hours":null,"exercise_resume_weeks":{"min":0,"max":1,"unit":"weeks","qualifier":"Light activity usually continues; intensity limited by fatigue, rash, diarrhea or cardiac precautions."},"final_result_months":{"min":2,"max":6,"unit":"months","qualifier":"Response is judged by imaging after several cycles; depends on tumor type and agent."},"fly_home_after_days":{"min":1,"max":3,"unit":"days","qualifier":"After first dose, oncology team usually wants early tolerance observed; depends on agent and infusion reactions."},"follow_up_visits":[{"purpose":"assessment","after":{"min":7,"max":21,"unit":"days","qualifier":"Early tolerance check with blood tests and side-effect review."},"requirement":"routine"},{"purpose":"result_review","after":{"min":56,"max":90,"unit":"days","qualifier":"First response imaging and blood markers; timing depends on agent and cancer type."},"requirement":"routine"}],"indications":["Cancers with molecular targets: HER2, EGFR, ALK, BRAF, BCR-ABL","Hematologic malignancies and solid tumors with a matched targeted agent","Some non-cancer conditions with defined molecular targets"],"main_risks":["Skin reactions such as rash and dryness","Diarrhea, nausea and other gastrointestinal effects","Liver enzyme elevation","Hypertension, cardiac effects or bleeding with certain agents","Infusion reactions with antibody-based agents","Blood count changes"],"pain":"Treatment itself is painless apart from IV cannulation. Side effects such as rash, mouth sores or joint aches are usually mild to moderate.","preparation":["Molecular target or biomarker confirmed by tissue or blood testing","Baseline blood tests and organ function assessment","Review of current medications and supplements with the oncology team","Baseline cardiac or other agent-specific assessment where required","Discussion of expected side effects and contraception where relevant"],"recovery_timeline":[{"phase":"Treatment day","description":"Oral dose started or infusion given with observation for reactions.","restrictions":["Report fever or breathing difficulty immediately","Follow agent-specific food and drug rules"]},{"phase":"First 2 weeks","description":"Early side effects such as rash, diarrhea or fatigue may appear and are managed with supportive care.","restrictions":["Avoid sun exposure","Avoid new supplements without approval"]},{"phase":"Ongoing cycles","description":"Treatment continues with periodic blood tests and imaging to assess response.","restrictions":["Contraception where relevant","Avoid grapefruit with some agents"]}],"rehabilitation_days":{"min":0,"max":3,"unit":"days","qualifier":"Ordinary activity resumes quickly; longer if infusion reactions or fatigue occur."},"result_longevity":"Response lasts as long as the drug is effective, often months to several years. Acquired resistance eventually develops in many cancers.","revision_rate_pct":null,"scars":"No incisions or scars; only minor puncture marks from IV cannulation.","sessions_or_stages":{"sessions":{"min":4,"max":13,"unit":"visits","qualifier":"Infusion-based schedule every 1-3 weeks until first imaging; oral agents need no infusion visits."},"stages":[{"code":"biomarker_confirmation","label":"Biomarker confirmation and baseline tests","after":{"min":0,"max":0,"unit":"days","qualifier":"Before first dose."}},{"code":"treatment_start","label":"First dose or infusion","after":{"min":0,"max":7,"unit":"days","qualifier":"Starts once testing is confirmed."}},{"code":"response_assessment","label":"First response imaging","after":{"min":56,"max":90,"unit":"days","qualifier":"After several cycles."}}],"qualifier":"Treatment continues until progression or intolerance; typical first-phase schedule shown."},"success":{"metric":"Objective tumor response rate at first imaging","value":60,"unit":"percent","horizon":"2-3 months","population":"Adults with biomarker-matched advanced cancer receiving a matched targeted agent","evidence_status":"limited"},"techniques":[{"name":"Small-molecule inhibitors (oral, e.g. tyrosine kinase inhibitors)","suits_whom":"Patients whose tumor carries a matching targetable alteration","recovery":"No recovery period; usually taken continuously at home with periodic monitoring."},{"name":"Monoclonal antibodies (intravenous or subcutaneous)","suits_whom":"Patients with target-expressing tumors such as HER2-positive cancers","recovery":"Given at scheduled infusion visits; usually no recovery time beyond infusion-related effects."},{"name":"Antibody-drug conjugates","suits_whom":"Selected patients with target-expressing cancers and suitable prior treatment history","recovery":"Given at scheduled infusion visits with monitoring for agent-specific toxicity."}],"treatment_conditions":["outpatient"],"treatment_duration_hours":{"min":0.5,"max":3,"unit":"hours","qualifier":"Per infusion visit; first infusion is longest. Oral agents are taken at home."},"initial_assessment_documents":["Pathology report with tumor type and stage","Molecular or genomic testing report","Recent CT or PET-CT scans","Summary of previous cancer treatments","Recent blood test results","Oncologist's latest treatment notes (if available)"],"travel_trips":{"min":2,"max":3,"one_trip_possible":false,"qualifier":"Start visit with first dose and tolerance check, then response imaging at 2-3 months; routine monitoring at home."},"clinic_checks":{"status":"ok","items":[{"id":"C1","text":"Check that your tumor has been tested for the drug's target. Why: the drug is chosen for a specific target found in the tumor","scope":"procedure","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet","host":"cancer.gov","quote":"Most of the time, your tumor will need to be tested to see if it contains targets for which there is a drug.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C2","text":"Check the qualifications of the medical team that will treat you","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Have you checked the qualifications of the medical team treating you?","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C3","text":"Make sure you are clear how your aftercare will be coordinated after treatment abroad","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Ensure you're clear about how your aftercare will be coordinated.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C4","text":"Check that the surgeon who consults with you is the same person who will carry out the procedure","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Check that the surgeon you consult with, will be the same person carrying out the procedure.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C5","text":"Expect two consultations with the treating surgeon before any surgery, which also gives you time to reconsider","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/conditions/cosmetic-procedures/cosmetic-surgery-abroad/","host":"nhs.uk","quote":"You should have 2 consultations with the surgeon treating you before any surgery.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"red_flags":{"status":"ok","items":[{"id":"F1","text":"Pressure to decide quickly, or cheap time-limited offers to book now","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"F2","text":"The doctor you consult may not be the one who actually treats you","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Check that the surgeon you consult with, will be the same person carrying out the procedure.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"F3","text":"Adverts or information promising complete success for the treatment","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Any advert or information that guarantees complete success should raise concerns.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"warning_signs":{"status":"ok","items":[{"id":"W1","text":"Unusual bleeding or bruising during targeted therapy","urgency":"contact_clinic","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/side-effects/bleeding-bruising","host":"cancer.gov","quote":"Some cancer treatments, such as chemotherapy and targeted therapy, can increase your risk of bleeding and bruising.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W2","text":"Diarrhea that lasts or becomes more severe","urgency":"contact_clinic","general":false,"source":{"url":"https://cancer.gov/about-cancer/treatment/side-effects/diarrhea","host":"cancer.gov","quote":"Ask the health care team about when you should call them if the diarrhea lasts or becomes more severe.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W3","text":"Fever higher than your care team expects","urgency":"contact_clinic","general":true,"source":{"url":"https://mdanderson.org/patients-family/diagnosis-treatment/emotional-physical-effects/targeted-therapy-side-effects.html","host":"mdanderson.org","quote":"A fever higher than what your care team told you to expect","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"take_home":{"status":"ok","items":[{"id":"T1","text":"Shows which follow-up tests are due and which doctors are responsible for care","document":"written aftercare plan","source":{"url":"https://www.cdc.gov/cancer/survivors/life-after-cancer/survivorship-care-plans.htm","host":"cdc.gov","quote":"Your plan should say when you need to get follow-up tests, and which doctors are responsible for your care.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":403}},{"id":"T2","text":"Gives the home doctor an up-to-date, clear picture of the treatment received","document":"end of treatment summary","source":{"url":"https://cht.nhs.uk/services/clinical-services/oncology/end-of-treatment-summary","host":"cht.nhs.uk","quote":"It also provides the GP with an up-to-date and clear understanding of the patient's treatment.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"T3","text":"Ask for copies of all prescriptions before you leave","document":"prescription copies","source":{"url":"https://travelhealthpro.org.uk/news/699/travelling-abroad-for-treatment","host":"travelhealthpro.org.uk","quote":"Remember to ask for copies of all your treatment records, including prescriptions, scans and x-rays before you leave.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"alternatives":{"status":"ok","items":[{"id":"A1","text":"You want a treatment that may slow or stop cancer growth","name":"Chemotherapy","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/chemotherapy","host":"cancer.gov","quote":"Chemotherapy can be used to cure cancer, lessen the chance it will return, or stop or slow its growth.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200},"operation_id":37},{"id":"A2","text":"You want treatment that helps your immune system fight the cancer","name":"Immunotherapy","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy","host":"cancer.gov","quote":"Immunotherapy is a type of cancer treatment that helps your immune system fight cancer.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200},"operation_id":283}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"technique_details":{"status":"ok","items":[{"id":"small-molecule-inhibitors","name":"Small-molecule inhibitors (oral, e.g. tyrosine kinase inhibitors)","how_it_works":{"text":"Small drugs enter cells and act on targets inside them","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet","host":"cancer.gov","quote":"Small-molecule drugs are small enough to enter cells easily, so they are used for targets that are inside cells.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":null},{"id":"monoclonal-antibodies","name":"Monoclonal antibodies (intravenous or subcutaneous)","how_it_works":{"text":"Antibodies attach to specific targets found on cancer cells","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet","host":"cancer.gov","quote":"These proteins are designed to attach to specific targets found on cancer cells.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":null},{"id":"antibody-drug-conjugates","name":"Antibody-drug conjugates","how_it_works":{"text":"Antibodies are linked to cell-killing substances that reach cancer cells","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet","host":"cancer.gov","quote":"Some monoclonal antibodies are combined with cell-killing substances such as toxins, chemotherapy drugs, or radiation.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":null}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1}}},"techniques":[{"id":"small-molecule-inhibitors","name":"Small-molecule inhibitors (oral, e.g. tyrosine kinase inhibitors)","how_it_works":{"id":"H1","text":"Small drugs enter cells and act on targets inside them","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet","host":"cancer.gov","quote":"Small-molecule drugs are small enough to enter cells easily, so they are used for targets that are inside cells.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"not_collected"},"suits_whom":"Patients whose tumor carries a matching targetable alteration","price_from":{"status":"missing","reason":"not_collected"},"recovery":"No recovery period; usually taken continuously at home with periodic monitoring."},{"id":"monoclonal-antibodies","name":"Monoclonal antibodies (intravenous or subcutaneous)","how_it_works":{"id":"H1","text":"Antibodies attach to specific targets found on cancer cells","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet","host":"cancer.gov","quote":"These proteins are designed to attach to specific targets found on cancer cells.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"not_collected"},"suits_whom":"Patients with target-expressing tumors such as HER2-positive cancers","price_from":{"status":"missing","reason":"not_collected"},"recovery":"Given at scheduled infusion visits; usually no recovery time beyond infusion-related effects."},{"id":"antibody-drug-conjugates","name":"Antibody-drug conjugates","how_it_works":{"id":"H1","text":"Antibodies are linked to cell-killing substances that reach cancer cells","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet","host":"cancer.gov","quote":"Some monoclonal antibodies are combined with cell-killing substances such as toxins, chemotherapy drugs, or radiation.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"not_collected"},"suits_whom":"Selected patients with target-expressing cancers and suitable prior treatment history","price_from":{"status":"missing","reason":"not_collected"},"recovery":"Given at scheduled infusion visits with monitoring for agent-specific toxicity."}],"alternatives":{"status":"ok","items":[{"id":"A1","text":"You want a treatment that may slow or stop cancer growth","name":"Chemotherapy","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/chemotherapy","host":"cancer.gov","quote":"Chemotherapy can be used to cure cancer, lessen the chance it will return, or stop or slow its growth.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200},"operation_id":37},{"id":"A2","text":"You want treatment that helps your immune system fight the cancer","name":"Immunotherapy","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy","host":"cancer.gov","quote":"Immunotherapy is a type of cancer treatment that helps your immune system fight cancer.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200},"operation_id":283}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"diagnostic":{"status":"not_applicable"},"country":{"why":{"status":"ok","items":[{"id":"Y1","text":"Turkey's Ministry of Health publishes lists of authorized healthcare providers and facilitators holding authorization certificates","specialties":[],"source":{"url":"https://shgmturizmdb.saglik.gov.tr/EN-69410/announcements.html","host":"shgmturizmdb.saglik.gov.tr","quote":"Updated lists of healthcare providers and facilitators that have been granted authorization certificates by the Ministry","tier":"government","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-05-11","version":1},"travel":{"status":"ok","items":[{"id":"V1","item":"visa","audience":"uk","volatile":true,"text":"UK citizen passport holders can visit Turkey without a visa for up to 90 days in any 180-day period, for business or tourism","source":{"url":"https://www.gov.uk/foreign-travel-advice/turkey/entry-requirements","host":"gov.uk","quote":"You can visit Turkey without a visa for up to 90 days in any 180-day period, for business or tourism.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V2","item":"visa","audience":"us","volatile":true,"text":"US ordinary passport holders are exempt from a visa for up to 90 days in any 180-day period in Turkey","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/Turkey.html","host":"travel.state.gov","quote":"Ordinary passport holders are exempted from visa up to 90 days in any 180-day period.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V3","item":"passport_validity","audience":"uk","volatile":true,"text":"A UK passport must expire at least 150 days after arrival in Turkey and have at least 1 blank page","source":{"url":"https://www.gov.uk/foreign-travel-advice/turkey/entry-requirements","host":"gov.uk","quote":"To enter Turkey, your passport must have an ‘expiry date’ at least 150 days after the date you arrive and at least 1 blank page.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V4","item":"passport_validity","audience":"us","volatile":true,"text":"A US passport must be valid for six months beyond the entry date into Turkey","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/Turkey.html","host":"travel.state.gov","quote":"Passports must be valid for six months beyond your entry date.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V5","item":"prescriptions","audience":"uk","volatile":false,"text":"British prescriptions are not accepted in pharmacies in Turkey","source":{"url":"https://www.gov.uk/foreign-travel-advice/turkey/health","host":"gov.uk","quote":"British prescriptions are not accepted in pharmacies in Turkey.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V6","item":"emergency_number","audience":"all","volatile":false,"text":"Dial 112 and ask for an ambulance in Turkey","source":{"url":"https://www.gov.uk/foreign-travel-advice/turkey/health","host":"gov.uk","quote":"Dial 112 and ask for an ambulance.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-11","next_check_at":"2026-12-11","version":1},"other_countries_with_page":["austria","azerbaijan","china","egypt","germany","india","israel","italy","latvia","malaysia","poland","republic-of-korea","spain","switzerland","thailand","ukraine","united-states"]},"often_combined_with":{"status":"missing","reason":"not_collected"},"reviews":{"avg_rating":4.56,"count":2553,"scope":"clinic","rating_scale":5,"pros":{"status":"missing","reason":"not_collected"},"cons":{"status":"missing","reason":"not_collected"}},"current":{"seo_text":"<p>Targeted therapy in Turkey generally costs from _op_284_price_from_ to _op_284_price_to_ per treatment cycle. Your final expenses depend on the specific drug protocol, genomic profiling requirements, and the hospital tier. In the United States, patients often face average costs of _price_compare_US_average_ for similar treatments. Turkey provides significant geographic savings of approximately _price_percent_discount_%. Most programs in Istanbul and Ankara include oncologist consultations, blood work, and airport transfers.</p>\n\n<ul>\n<li><strong>Lutetium-177 therapy:</strong> _op_830_price_from_ to _op_830_price_to_ for advanced prostate cancer or neuroendocrine tumors.</li>\n<li><strong>Actinium-225 therapy:</strong> _op_1653_price_from_ to _op_1653_price_to_ for targeted alpha-particle treatment of metastatic cancers.</li>\n<li><strong>Standard monoclonal antibodies:</strong> Typically range between $1,000 and $12,000 depending on the medication brand.</li>\n<li><strong>Diagnostic biomarkers:</strong> Molecular testing and PET/CT scans usually add an initial $700 to $1,500.</li>\n</ul>\n\n<p><strong>Bookimed Expert Insight:</strong> Choosing centers with international affiliations offers the highest value for complex cases. Anadolu Medical Center maintains a strict partnership with Johns Hopkins Medicine to follow US-standard protocols. Meanwhile, Memorial Şişli Hospital was the first in Turkey to earn Joint Commission International (JCI) accreditation. These top-tier facilities provide 600-gene cancer profiling, ensuring you pay for the most effective drug rather than a trial-and-error approach.</p>","faq":[{"q":"What is targeted therapy and how does it differ from chemotherapy?","a":"<p>Targeted therapy is precision medicine that uses drugs to attack specific genetic mutations or proteins driving cancer growth. Unlike chemotherapy, which kills all rapidly dividing cells, this approach spares healthy tissue, reduces systemic side effects like hair loss, and requires specialized genomic testing before treatment begins.</p> <ul> <li><strong>Cellular mechanism:</strong> Targeted drugs block growth signals while chemotherapy acts as a broad cytotoxic poison.</li> <li><strong>Selectivity level:</strong> This method focuses on unique tumor markers, minimizing damage to normal, healthy cells.</li> <li><strong>Effect type:</strong> It is primarily cytostatic, meaning it stops cancer cells from multiplying and spreading.</li> <li><strong>Common side effects:</strong> Patients typically experience specific rashes or diarrhea rather than systemic fatigue or nausea.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Turkish oncology centers like Anadolu Medical Center often combine targeted therapy with immunotherapy protocols. This dual approach is facilitated by their direct collaboration with Johns Hopkins Medicine. By using genomic sequencing first, surgeons can select precise drugs like Lutetium-177, which may cost _op_830_price_from_ in Turkey compared to nearly _price_compare_US_average_ elsewhere.</p> <p><strong>Patient Consensus:</strong> Many patients find they can continue working remotely during treatment since it avoids the severe neutropenia of chemo. Everyone emphasizes confirming that the specific mutation-targeted drug is in stock before flying to Istanbul.</p>"},{"q":"Which cancers are most commonly treated with targeted therapy in Turkey?","a":"<p>Targeted therapy in Turkey primarily treats lung, breast, and colorectal cancers by identifying specific genetic mutations. Medical oncologists frequently prescribe HER2 inhibitors for breast cancer and EGFR or ALK inhibitors for non-small cell lung cancer. Specialized centers in Istanbul also prioritize melanoma, kidney, and gastrointestinal stromal tumors.</p> <ul> <li><strong>Lung cancer focus:</strong> Clinics target EGFR and ALK mutations in non-small cell lung cancer patients.</li> <li><strong>Breast cancer protocols:</strong> HER2-positive cases commonly receive trastuzumab or pertuzumab at ESMO-certified oncology centers.</li> <li><strong>Gastrointestinal treatments:</strong> Surgeons and oncologists use KIT inhibitors for stromal tumors and bevacizumab for colorectal.</li> <li><strong>Genetic testing access:</strong> Top hospitals like Anadolu Medical Center provide rapid NGS panel testing for mutations.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Turkish oncology centers often follow U.S. protocols due to high-level affiliations, such as Anadolu Medical Center’s partnership with Johns Hopkins Medicine. These clinics provide EGFR and ALK inhibitors at significantly lower costs than the US, where similar treatments average _price_compare_US_average_. Patients can save up to _price_percent_discount_% while receiving care from professors with over 20 years of experience who have trained at global institutions like MD Anderson or Rambam.</p> <p><strong>Patient Consensus:</strong> Patients emphasize the importance of completing comprehensive NGS mutation testing before traveling. Many choose Turkey for the speed of starting targeted drug protocols once a genetic match is confirmed.</p>"},{"q":"Are Turkish oncology centers accredited?","a":"<p>Leading Turkish oncology centers maintain elite international accreditations, ranking Turkey among the top five countries globally for facilities holding Joint Commission International (JCI) certification. These standards ensure over 1,200 quality measures are met, matching protocols used at top-tier medical institutions like the Mayo Clinic.</p> <ul> <li><strong>Core accreditation:</strong> Over 40–50 hospitals maintain JCI status, focusing on patient safety and hygiene.</li> <li><strong>Cancer specialization:</strong> Anadolu Medical Center holds European Society for Medical Oncology (ESMO) and OECI certifications.</li> <li><strong>Quality management:</strong> Major groups like Memorial and Medipol consistently maintain ISO 9001:2015 quality standards.</li> <li><strong>Global partnerships:</strong> Top facilities often affiliate with U.S. leaders like Johns Hopkins Medicine International.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Anadolu Medical Center stands out because it holds both the OECI and IASIOS certificates specifically for interventional oncology. While many Turkish hospitals have JCI, finding one with these cancer-specific European credentials usually signals a more specialized multidisciplinary tumor board approach.</p> <p><strong>Patient Consensus:</strong> Patients emphasize verifying that a specific hospital's oncology department is JCI-certified on the official registry before booking. They also recommend bringing records translated into English to ensure smooth processing within these accredited systems.</p>"},{"q":"What diagnostic tools are used to personalize treatment?","a":"<p>Clinicians use high-throughput diagnostic tools like next-generation sequencing, liquid biopsies, and molecular profiling to personalize targeted therapy. These advanced technologies identify specific genetic mutations, such as EGFR or ALK, allowing surgeons to select medications that precisely attack cancer cells while sparing healthy tissue.</p> <ul> <li><strong>Next-generation sequencing:</strong> Rapidly identifies actionable mutations through comprehensive genomic profiling of tumor tissue.</li> <li><strong>Liquid biopsies:</strong> Uses blood samples to analyze circulating tumor DNA for non-invasive monitoring.</li> <li><strong>Molecular testing:</strong> Employs IHC and FISH testing to detect protein expression and genetic fusions.</li> <li><strong>PD-L1 testing:</strong> Determines if immunotherapy is effective by measuring specific biomarker presence in cells.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Turkish oncology centers like Anadolu Medical Center maintain a strategic partnership with Johns Hopkins Medicine. This collaboration allows patients to receive treatment based on specific U.S. clinical protocols. Our data shows that top-tier facilities combine these international standards with AI-supported 3 Tesla MRI and digital PET/CT to refine diagnostic accuracy.</p> <p><strong>Patient Consensus:</strong> Patients emphasize the importance of liquid biopsies to track how tumors evolve over time. Many recommend verifying that clinics use CAP-certified labs for genetic profiling to ensure the most accurate results for rare mutations.</p>"},{"q":"What types of targeted therapy are available in Turkey?","a":"<p>Turkey offers a comprehensive spectrum of targeted therapies including monoclonal antibodies, small molecule inhibitors, and tyrosine kinase inhibitors (TKIs). Specialized oncology centers in Istanbul focus on precision medicine, utilizing genetic profiling to match patients with FDA-approved drugs for breast, lung, and colorectal cancers.</p> <ul> <li><strong>Available drugs:</strong> Includes trastuzumab (Herceptin), pertuzumab, osimertinib (Tagrisso), and PARP inhibitors like olaparib.</li> <li><strong>Advanced options:</strong> Radionuclide treatments such as Lutetium-177 and Actinium-225 are available at Anadolu Medical Center.</li> <li><strong>Clinical protocols:</strong> Leading facilities follow ESMO and Johns Hopkins Medicine protocols for treatment cycles.</li> <li><strong>Cost range:</strong> Targeted therapy cycles typically range from _op_284_price_from_ to _op_284_price_to_ per session.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> While many clinics offer targeted drugs, the highest success rates are found at centers with integrated NGS labs. Anadolu Medical Center and Memorial Sisli utilize in-house molecular testing to identify specific mutations. This eliminates the 2-week wait typical for external lab results, allowing treatment to begin faster.</p> <p><strong>Patient Consensus:</strong> Patients emphasize the importance of bringing original pathology slides from home. Having these reviewed by Turkish experts ensures the targeted drug matches the tumor’s specific genetic profile without repeating invasive biopsies.</p>"},{"q":"Do Turkish hospitals provide support for international patients?","a":"<p>Turkish hospitals provide comprehensive support for international patients through dedicated departments that manage logistics, translation, and medical coordination. Major facilities like Anadolu Medical Center and Memorial Health Group offer all-inclusive services covering airport transfers, local hotel bookings, and 24/7 interpreter support in over 20 languages.</p> <ul> <li><strong>Logistical assistance:</strong> Centers coordinate VIP airport pickups and private transportation to treatments.</li> <li><strong>Administrative guidance:</strong> Dedicated coordinators manage visa invitation letters and hospital admission paperwork.</li> <li><strong>Clinical coordination:</strong> Patients receive medical second opinions and help transferring international records.</li> <li><strong>Language services:</strong> Multilingual staff provide free 24/7 translation at clinics and pharmacies.</li> <li><strong>Government support:</strong> A national assistance unit offers oral translation for all foreign visitors.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Quality signals for international care are strongest at Anadolu Medical Center due to its Johns Hopkins Medicine affiliation. This partnership ensures all diagnostic and treatment protocols for targeted therapy align with U.S. standards while maintaining Turkey’s significantly lower costs.</p> <p><strong>Patient Consensus:</strong> Patients value the seamless experience provided by personal coordinators who handle everything from local SIM cards to post-treatment hotel stays. Many recommend confirming your specific coordinator's availability before arrival to ensure smooth communication during consultations.</p>"}],"h2":[{"text":"トルコでの分子標的治療費用について今すぐご確認ください","kind":"content"},{"text":"Bookimedでのお客様のメリットと保証","kind":"content"},{"text":"Bookimed専属アシスタント","kind":"content"},{"text":"トルコの最高の分子標的治療クリニックをご発見ください：11件の認証済み選択肢と料金","kind":"content"},{"text":"トルコでの分子標的治療概要","kind":"content"},{"text":"トルコでの分子標的治療医療診断をお受けください：23名の経験豊富な医師に今すぐご相談","kind":"content"},{"text":"Bookimed患者のビデオストーリー","kind":"content"},{"text":"Bookimedに関するレビュー：患者様の洞察を発見","kind":"content"},{"text":"このコンテンツを共有","kind":"content"},{"text":"トルコでの分子標的治療に関するFAQ","kind":"content"},{"text":"無料相談を受ける","kind":"content"}]},"placeholders":{"price_from":"{{price_from}}","clinics_count":"{{clinics_count}}","cities_count":"{{cities_count}}","savings_pct":"{{savings_pct}}","data_date":"{{data_date}}"},"legal":{"restricted_markets":{"status":"missing","reason":"not_collected"}},"conflicts":[]}